Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86


Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?

Botticelli A, Borro M, Onesti CE, Strigari L, Gentile G, Cerbelli B, Romiti A, Occhipinti M, Sebastiani C, Lionetto L, Marchetti L, Simmaco M, Marchetti P, Mazzuca F.

PLoS One. 2016 Sep 22;11(9):e0163105. doi: 10.1371/journal.pone.0163105. eCollection 2016.


5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.

Onesti CE, Botticelli A, La Torre M, Borro M, Gentile G, Romiti A, Lionetto L, Petremolo A, Occhipinti M, Roberto M, Falcone R, Simmaco M, Marchetti P, Mazzuca F.

Anticancer Drugs. 2017 Mar;28(3):322-326. doi: 10.1097/CAD.0000000000000453.


Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.

Borro M, Botticelli A, Mazzuca F, Onesti EC, Gentile G, Romiti A, Cerbelli B, Mazzotti E, Marchetti L, Lionetto L, Simmaco M, Marchetti P.

Oncotarget. 2017 Feb 21;8(8):14050-14057. doi: 10.18632/oncotarget.12571.


Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ, Iacopetta B.

Br J Cancer. 2009 Sep 15;101(6):998-1004. doi: 10.1038/sj.bjc.6605239. Epub 2009 Aug 11.


Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.

Link KH, Kornmann M, Leder G, Pillasch AF, Sunelaitis E, Schatz M, Pressmar J, Beger HG.

Gan To Kagaku Ryoho. 1999 Feb;26(3):269-81. Review.


DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.

Nahid NA, Apu MNH, Islam MR, Shabnaz S, Chowdhury SM, Ahmed MU, Nahar Z, Islam MS, Islam MS, Hasnat A.

Cancer Chemother Pharmacol. 2018 Jan;81(1):119-129. doi: 10.1007/s00280-017-3478-3. Epub 2017 Nov 13.


A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.

Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F.

Anticancer Drugs. 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492.


Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.

Focan C, Levi F, Kreutz F, Focan-Henrard D, Lobelle JP, Adam R, Dallemagne B, Jehaes C, Markiewicz S, Weerts J, Bismuth H, Jasmin C, Misset JL.

Anticancer Drugs. 1999 Apr;10(4):385-92.


Thymidylate synthase pharmacogenetics in colorectal cancer.

Marsh S, McLeod HL.

Clin Colorectal Cancer. 2001 Nov;1(3):175-8; discussion 179-81. Review.


[Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].

Popov I, Jelić S, Radosavljević D, Nikolić-Tomasević A.

Srp Arh Celok Lek. 1998 Sep-Oct;126(9-10):355-61. Serbian.


Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.

Teh LK, Hamzah S, Hashim H, Bannur Z, Zakaria ZA, Hasbullani Z, Shia JK, Fijeraid H, Md Nor A, Zailani M, Ramasamy P, Ngow H, Sood S, Salleh MZ.

Ther Drug Monit. 2013 Oct;35(5):624-30. doi: 10.1097/FTD.0b013e318290acd2.


Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer.

Kim KR, Yoon JH, Shim HJ, Hwang JE, Bae WK, Chung IJ, Kim HN, Shin MH, Cho SH.

Oncol Lett. 2017 Aug;14(2):2491-2498. doi: 10.3892/ol.2017.6414. Epub 2017 Jun 19.


Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.

Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E.

BMC Med. 2012 Nov 8;10:135. doi: 10.1186/1741-7015-10-135.


Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

Amstutz U, Farese S, Aebi S, Largiadèr CR.

Pharmacogenomics. 2009 Jun;10(6):931-44. doi: 10.2217/pgs.09.28.


Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.

Wen F, Tang R, Sang Y, Li M, Hu Q, Du Z, Zhou Y, Zhang P, He X, Li Q.

Cancer Sci. 2013 Oct;104(10):1330-8. doi: 10.1111/cas.12224. Epub 2013 Jul 30.


Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.


Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.

Link KH, Sunelaitis E, Kornmann M, Schatz M, Gansauge F, Leder G, Formentini A, Staib L, Pillasch J, Beger HG.

Cancer. 2001 Dec 1;92(11):2746-53.


Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.

Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M; German 5-FU Toxicity Study Group.

J Clin Oncol. 2008 May 1;26(13):2131-8. doi: 10.1200/JCO.2006.10.4182. Epub 2008 Feb 25.


MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.

van Huis-Tanja LH, Gelderblom H, Punt CJ, Guchelaar HJ.

Pharmacogenet Genomics. 2013 Apr;23(4):208-18. doi: 10.1097/FPC.0b013e32835ee8e1.


Supplemental Content

Support Center